Nastech to host free Web cast on emerging RNAi programs and technology

Nastech Pharmaceutical Company Inc.


Webcast Alert: Nastech to Host free Webcast on emerging RNAi Programs and Technology on November 9, 2006, at 10:30 AM U.S. East Coast time

What: RNAi webinar on the science and business of RNAi therapeutics followed by a Q&A session. Questions may be emailed in advance to or during the event through the webinar interface (your anonymity on the Q&A is assured)

When: Thursday, November 9, 2006, at 10:30-11:15 AM U.S. East Coast time

How: Live over the Internet via a simple advanced registration at

Where: Webinar will be available at once you are registered

Contact: Matthew Haines of Noonan Russo at 212-845-4235 or

If you are unable to participate during the live RNAi webinar webcast, an archive and replay will be available for 30 days via Nastech's website at


Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK; is an emerging leader in the development of RNAi therapeutics. Key developments in Nastech's RNAi program are:
9/26/06 - Nastech Receives $1.9 Million National Institute of Health-R01 Grant for Development of RNAi Therapeutics to Prevent and Treat Influenza
8/29/06 - Nastech Awarded Development Grant for RNAi Therapeutics to Prevent and Treat Influenza
3/16/06 - Nastech Presents Successful In Vitro and In Vivo Results with Its RNAi Therapeutics Program for Influenza
2/23/06 - Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea
11/17/05 - Nastech Presents Positive Results on RNA Interference Program for Treatment of Rheumatoid Arthritis at the American College of Rheumatology Annual Scientific Meeting
7/20/05 - Alnylam Grants Nastech a License to Develop RNAi Therapeutics Against TNF-alpha
4/5/05 - Nastech Announces RNAi Therapeutics-Based Rheumatoid Arthritis Clinical Study Collaboration
4/5/05 - Nastech presents promising In Vivo research findings with RNAi-Based Therapeutics for Rheumatoid Arthritis at the 2005 American Society for Biochemistry and Molecular Biology Annual Meeting
2/2/04 - Nastech obtains a non-exclusive license from the Carnegie Institute of Washington, D.C. to the Fire et al patents and patent applications titled "Genetic Inhibition by Double-Stranded RNA" (including U.S. Patent # 6,506,559 B1)

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.